首页 > 最新文献

Contraception最新文献

英文 中文
Contraception and abortion attitudes among military medical students: An exploratory study. 军医学生的避孕和堕胎态度:一项探索性研究。
Pub Date : 2024-05-16 DOI: 10.1016/j.contraception.2024.110489
Nicole M Mahr, Jill E Brown

Objectives: To investigate military medical students' attitudes toward contraception and abortion after clerkships.

Study design: We adapted a survey of civilian medical student attitudes for military students. We asked how clerkships changed perspectives and comfort discussing these topics.

Results: Eighty-five (85%) of 100 respondents felt more comfortable discussing contraception and abortion after clerkships. More students changed perspectives on contraception than abortion (29% vs 17%, p = 0.043). Students noted limited exposure to abortion.

Conclusions: Clerkships increased comfort discussing contraception and abortion but were unlikely to change their attitudes.

Implications: More exposure to abortion care is needed.

研究目的:调查军医学生在实习结束后对避孕和人工流产的态度:研究设计:研究设计:我们针对军医学生改编了一项针对平民医学生态度的调查。我们询问了实习对讨论这些话题的观点和舒适度有何改变:结果:在 100 名受访者中,有 85% 的人在实习后更愿意讨论避孕和流产问题。与堕胎相比,更多学生改变了对避孕的看法(29% 对 17%,P=0.043)。学生们指出,他们接触到的人工流产护理有限:实习提高了讨论避孕和人工流产的舒适度,但不太可能改变对这些话题的态度。需要更多地接触人工流产护理。
{"title":"Contraception and abortion attitudes among military medical students: An exploratory study.","authors":"Nicole M Mahr, Jill E Brown","doi":"10.1016/j.contraception.2024.110489","DOIUrl":"10.1016/j.contraception.2024.110489","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate military medical students' attitudes toward contraception and abortion after clerkships.</p><p><strong>Study design: </strong>We adapted a survey of civilian medical student attitudes for military students. We asked how clerkships changed perspectives and comfort discussing these topics.</p><p><strong>Results: </strong>Eighty-five (85%) of 100 respondents felt more comfortable discussing contraception and abortion after clerkships. More students changed perspectives on contraception than abortion (29% vs 17%, p = 0.043). Students noted limited exposure to abortion.</p><p><strong>Conclusions: </strong>Clerkships increased comfort discussing contraception and abortion but were unlikely to change their attitudes.</p><p><strong>Implications: </strong>More exposure to abortion care is needed.</p>","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110489"},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug-drug interactions between antiretrovirals and hormonal contraception: An updated systematic review. 抗逆转录病毒药物与荷尔蒙避孕药之间的药物相互作用:最新系统综述。
Pub Date : 2024-05-16 DOI: 10.1016/j.contraception.2024.110490
Catherine S Todd, Lara Lorenzetti, Aamirah Mussa, Kathleen Ridgeway, Chelsea Morroni, Kavita Nanda

Objective: To summarize and update information regarding drug-drug interactions (DDIs) between antiretrovirals (ARVs) and hormonal contraceptives (HCs).

Study design: Systematic review.

Results: We included 49 articles, with clinical, ARV, or HC PK outcomes reported by 39, 25, and 30 articles, respectively, with some articles reporting outcomes in two or more categories. Fifteen of 18 articles assessing DDIs between efavirenz and progestin implants, emergency contraception, or combined hormonal intravaginal rings found higher pregnancy rates, luteal progesterone levels suggesting ovulation, or reduced progestin PK values. Five studies documented that CYP2B6 single nucleotide polymorphisms exacerbated this DDI. One cohort detected doubled bone density loss with concomitant depot medroxyprogesterone acetate (DMPA) and tenofovir disoproxil fumarate (TDF)-containing ART use versus TDF alone. No other studies described DDIs impacting clinical outcomes. Few adverse events were attributed to ARV-HC use with none exceeding Grade 2. Evidence quality was generally moderate, with dis-similar treatment and control groups, identifying and controlling for confounding, and minimizing attrition bias in the study design being the most frequent limitations.

Conclusion: TDF-DMPA DDIs warrant longer-term study on bone health and consideration of alternate combinations. For efavirenz-based ART, client counseling on relative risks, including both potential increase in pregnancy rate with concomitant efavirenz and implant use and lower pregnancy rates compared to other HCs even with concomitant efavirenz use, should continue to allow users comprehensive method choice.

Implications: Most ARVs and HCs may be used safely and effectively together. Efavirenz-based ART requires careful counseling and data for possible interactions between HCs and new ARV classes are anticipated.

目的总结并更新有关抗逆转录病毒药物(ARVs)与激素避孕药(HCs)之间药物相互作用(DDIs)的信息:系统综述 方法:我们在七个数据库中检索了从 2015 年 1 月 1 日到 2023 年 12 月 31 日的同行评审出版物,其中包括对同时使用抗逆转录病毒药物和激素避孕药的女性进行的研究,研究结果包括治疗效果或毒性、药代动力学 (PK) 或药效学。我们总结了研究结果,并使用核对表评估证据质量:我们共纳入了 49 篇文章,分别有 39、25 和 30 篇文章报告了临床、抗逆转录病毒或 HC PK 结果,其中一些文章报告了两个或多个类别的结果。在18篇评估依非韦伦与孕激素植入物、紧急避孕药或阴道内联合激素环之间DDIs的文章中,有15篇发现妊娠率升高、黄体孕酮水平提示排卵或孕激素PK值降低。五项研究表明,CYP2B6 单核苷酸多态性加剧了这种 DDI。一项队列研究发现,同时使用醋酸甲羟孕酮(DMPA)和富马酸替诺福韦二吡呋酯(TDF)抗逆转录病毒疗法与单独使用TDF相比,骨密度损失增加了一倍。没有其他研究描述了影响临床结果的 DDIs。因使用抗逆转录病毒药物而导致的不良反应很少,没有超过2级的不良反应。证据质量一般为中等,最常见的限制因素是治疗组和对照组不相似、混杂因素的识别和控制以及研究设计中自然减员偏倚的最小化:结论:大多数抗逆转录病毒药物和碳氢化合物可安全有效地同时使用。结论:大多数抗逆转录病毒药物和碳氢化合物可安全有效地联合使用,但 TDF-DMPA DDIs 需要对骨骼健康进行更长期的研究,并考虑替代组合。对于以依非韦伦为基础的抗逆转录病毒疗法,应继续向客户提供有关相对风险的咨询,包括同时使用依非韦伦和植入物可能增加的妊娠率,以及即使同时使用依非韦伦,妊娠率也低于其他抗逆转录病毒药物的妊娠率,以便用户能够全面选择治疗方法。
{"title":"Drug-drug interactions between antiretrovirals and hormonal contraception: An updated systematic review.","authors":"Catherine S Todd, Lara Lorenzetti, Aamirah Mussa, Kathleen Ridgeway, Chelsea Morroni, Kavita Nanda","doi":"10.1016/j.contraception.2024.110490","DOIUrl":"10.1016/j.contraception.2024.110490","url":null,"abstract":"<p><strong>Objective: </strong>To summarize and update information regarding drug-drug interactions (DDIs) between antiretrovirals (ARVs) and hormonal contraceptives (HCs).</p><p><strong>Study design: </strong>Systematic review.</p><p><strong>Results: </strong>We included 49 articles, with clinical, ARV, or HC PK outcomes reported by 39, 25, and 30 articles, respectively, with some articles reporting outcomes in two or more categories. Fifteen of 18 articles assessing DDIs between efavirenz and progestin implants, emergency contraception, or combined hormonal intravaginal rings found higher pregnancy rates, luteal progesterone levels suggesting ovulation, or reduced progestin PK values. Five studies documented that CYP2B6 single nucleotide polymorphisms exacerbated this DDI. One cohort detected doubled bone density loss with concomitant depot medroxyprogesterone acetate (DMPA) and tenofovir disoproxil fumarate (TDF)-containing ART use versus TDF alone. No other studies described DDIs impacting clinical outcomes. Few adverse events were attributed to ARV-HC use with none exceeding Grade 2. Evidence quality was generally moderate, with dis-similar treatment and control groups, identifying and controlling for confounding, and minimizing attrition bias in the study design being the most frequent limitations.</p><p><strong>Conclusion: </strong>TDF-DMPA DDIs warrant longer-term study on bone health and consideration of alternate combinations. For efavirenz-based ART, client counseling on relative risks, including both potential increase in pregnancy rate with concomitant efavirenz and implant use and lower pregnancy rates compared to other HCs even with concomitant efavirenz use, should continue to allow users comprehensive method choice.</p><p><strong>Implications: </strong>Most ARVs and HCs may be used safely and effectively together. Efavirenz-based ART requires careful counseling and data for possible interactions between HCs and new ARV classes are anticipated.</p>","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110490"},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Person-centered abortion care scale: Validation for medication abortion in the United States. 以人为本的人工流产护理量表:美国药物流产验证。
Pub Date : 2024-05-14 DOI: 10.1016/j.contraception.2024.110485
May Sudhinaraset, Jessica D Gipson, Michelle Kao Nakphong, Brenda Soun, Patience Afulani, Ushma Upadhyay, Rajita Patil

Objective: Medication abortions now make up the majority of abortions in the US, with new service delivery models such as telehealth; however, it is unclear how this may impact patient experiences. The objective of the study is to adapt and validate a person-centered abortion care (PCAC) scale for medication abortions that was developed in a global South context (Kenya) for use in the United States.

Study design: This study includes medication abortion patients from a hospital-based clinic who had one of two modes of service delivery: 1) telemedicine with no physical exam or ultrasound; or 2) in-person with clinic-based exams and ultrasounds. We conducted a sequential approach to scale development including: 1) defining constructs and item generation; 2) expert reviews; 3) cognitive interviews (n=12); 4) survey development and online survey data collection (N=182, including 45 telemedicine patients and 137 in-person patients); and 5) psychometric analyses.

Results: Exploratory factor analyses identified 29-items for the US-PCAC scale with three subscales: 1) Respect & Dignity (10 items), 2) Responsive & Supportive Care (9 items for the full scale, 1 additional mode-specific item each for in-person and telemedicine), and 3) Communication & Autonomy (10 items for the full scale, 1 additional item for telemedicine). The US-PCAC had high content, construct, and criterion validity. It also had high reliability, with a standardized alpha for the full 29-item US-PCAC scale of 0.95. The US-PCAC score was associated with overall satisfaction.

Conclusion: This study found high validity and reliability of a newly-developed person-centered abortion care scale for use in the US. As medication abortion provision expands, this scale can be used in quality improvement efforts.

Implications: This study found high validity and reliability of a newly-developed person-centered care scale for use in the United States for in-person and telemedicine medication abortion.

目的:在美国,随着远程医疗等新服务模式的出现,药物流产目前已占流产的大多数;然而,目前尚不清楚这可能会对患者的体验产生何种影响。本研究的目的是调整和验证以人为本的药物流产护理量表(PCAC),该量表是在全球南方国家(肯尼亚)开发的,可在美国使用:研究设计:本研究包括一家医院诊所的药物流产患者,他们接受了两种服务模式中的一种:1)无体格检查或超声波检查的远程医疗;或 2)有诊所检查和超声波检查的面对面服务。我们采用了一种循序渐进的量表开发方法,包括1)定义构造和项目生成;2)专家评审;3)认知访谈(12 人);4)调查开发和在线调查数据收集(182 人,包括 45 名远程医疗患者和 137 名亲临现场的患者);5)心理测量分析:探索性因子分析为美国-PCAC量表确定了29个项目,其中包括三个子量表:1)尊重与尊严(10个项目);2)响应与支持性护理(全量表9个项目,面诊和远程医疗各增加1个特定模式项目);3)沟通与自主(全量表10个项目,远程医疗增加1个项目)。US-PCAC 具有较高的内容效度、结构效度和标准效度。它的信度也很高,全量表 29 个项目的标准化α值为 0.95。US-PCAC得分与总体满意度相关:本研究发现,在美国使用新开发的以人为本的人工流产护理量表具有很高的有效性和可靠性。随着药物流产服务的扩大,该量表可用于质量改进工作:本研究发现,新开发的以人为本的护理量表具有很高的有效性和可靠性,适用于美国的现场和远程医疗药物流产。
{"title":"Person-centered abortion care scale: Validation for medication abortion in the United States.","authors":"May Sudhinaraset, Jessica D Gipson, Michelle Kao Nakphong, Brenda Soun, Patience Afulani, Ushma Upadhyay, Rajita Patil","doi":"10.1016/j.contraception.2024.110485","DOIUrl":"https://doi.org/10.1016/j.contraception.2024.110485","url":null,"abstract":"<p><strong>Objective: </strong>Medication abortions now make up the majority of abortions in the US, with new service delivery models such as telehealth; however, it is unclear how this may impact patient experiences. The objective of the study is to adapt and validate a person-centered abortion care (PCAC) scale for medication abortions that was developed in a global South context (Kenya) for use in the United States.</p><p><strong>Study design: </strong>This study includes medication abortion patients from a hospital-based clinic who had one of two modes of service delivery: 1) telemedicine with no physical exam or ultrasound; or 2) in-person with clinic-based exams and ultrasounds. We conducted a sequential approach to scale development including: 1) defining constructs and item generation; 2) expert reviews; 3) cognitive interviews (n=12); 4) survey development and online survey data collection (N=182, including 45 telemedicine patients and 137 in-person patients); and 5) psychometric analyses.</p><p><strong>Results: </strong>Exploratory factor analyses identified 29-items for the US-PCAC scale with three subscales: 1) Respect & Dignity (10 items), 2) Responsive & Supportive Care (9 items for the full scale, 1 additional mode-specific item each for in-person and telemedicine), and 3) Communication & Autonomy (10 items for the full scale, 1 additional item for telemedicine). The US-PCAC had high content, construct, and criterion validity. It also had high reliability, with a standardized alpha for the full 29-item US-PCAC scale of 0.95. The US-PCAC score was associated with overall satisfaction.</p><p><strong>Conclusion: </strong>This study found high validity and reliability of a newly-developed person-centered abortion care scale for use in the US. As medication abortion provision expands, this scale can be used in quality improvement efforts.</p><p><strong>Implications: </strong>This study found high validity and reliability of a newly-developed person-centered care scale for use in the United States for in-person and telemedicine medication abortion.</p>","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110485"},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing hospital vs. non-hospital-affiliated clinic adoption of abortion innovations and cash-pay availability during the COVID-19 pandemic: A secondary analysis of a United States nationwide survey. 比较医院与非医院附属诊所在 COVID-19 大流行期间采用人工流产创新技术和现金支付的情况:对美国全国性调查的二次分析。
Pub Date : 2024-05-01 DOI: 10.1016/j.contraception.2024.110493
Luisa Silva, Jessica K. Lee
{"title":"Comparing hospital vs. non-hospital-affiliated clinic adoption of abortion innovations and cash-pay availability during the COVID-19 pandemic: A secondary analysis of a United States nationwide survey.","authors":"Luisa Silva, Jessica K. Lee","doi":"10.1016/j.contraception.2024.110493","DOIUrl":"https://doi.org/10.1016/j.contraception.2024.110493","url":null,"abstract":"","PeriodicalId":93955,"journal":{"name":"Contraception","volume":"33 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141057239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A retrospective analysis of factors associated with deep contraceptive implant removals compared to superficial removals. 深部避孕植入物取出与表层取出的相关因素回顾性分析。
Pub Date : 2024-05-01 DOI: 10.1016/j.contraception.2024.110486
Paige D. Kendall, Wyanet Bresnitz, Jin Huang, Jeanelle Sheeder, A. Lazorwitz
{"title":"A retrospective analysis of factors associated with deep contraceptive implant removals compared to superficial removals.","authors":"Paige D. Kendall, Wyanet Bresnitz, Jin Huang, Jeanelle Sheeder, A. Lazorwitz","doi":"10.1016/j.contraception.2024.110486","DOIUrl":"https://doi.org/10.1016/j.contraception.2024.110486","url":null,"abstract":"","PeriodicalId":93955,"journal":{"name":"Contraception","volume":"31 1","pages":"110486"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141023941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time to treat the climate and nature crisis as one indivisible global health emergency. 是时候将气候和自然危机作为一个不可分割的全球健康紧急事件来对待了。
Pub Date : 2024-02-01 Epub Date: 2023-11-10 DOI: 10.1016/j.contraception.2023.110326
Kamran Abbasi, Parveen Ali, Virginia Barbour, Thomas Benfield, Kirsten Bibbins-Domingo, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Robert Mash, Peush Sahni, Wadeia Mohammad Sharief, Paul Yonga, Chris Zielinski
{"title":"Time to treat the climate and nature crisis as one indivisible global health emergency.","authors":"Kamran Abbasi, Parveen Ali, Virginia Barbour, Thomas Benfield, Kirsten Bibbins-Domingo, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Robert Mash, Peush Sahni, Wadeia Mohammad Sharief, Paul Yonga, Chris Zielinski","doi":"10.1016/j.contraception.2023.110326","DOIUrl":"10.1016/j.contraception.2023.110326","url":null,"abstract":"","PeriodicalId":93955,"journal":{"name":"Contraception","volume":"130 ","pages":"110326"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139076225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to the Letter to Editor 对给编辑的信的回应
Pub Date : 2009-03-01 DOI: 10.1016/J.CONTRACEPTION.2008.09.013
K. Henderson, Leslie Bernstein
{"title":"Response to the Letter to Editor","authors":"K. Henderson, Leslie Bernstein","doi":"10.1016/J.CONTRACEPTION.2008.09.013","DOIUrl":"https://doi.org/10.1016/J.CONTRACEPTION.2008.09.013","url":null,"abstract":"","PeriodicalId":93955,"journal":{"name":"Contraception","volume":"36 1","pages":"240-241"},"PeriodicalIF":0.0,"publicationDate":"2009-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83310471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Contraception
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1